Sun Pharma Advanced Research Company Ltd. (SPARC)
Market Closed
10 Aug, 10:00
XNSE XNSE Primary MSE ₹
207. 38
-5.83
-2.7344%
₹
42.66B Market Cap
- P/E Ratio
- Div Yield
2M Volume
0 Eps
₹ 213.21
Previous Close Want to track SPARC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
SPARC closed today lower at ₹207.38, a decrease of -2.7344% from yesterday's close, completing a monthly decrease of -12.0973% or -₹28.54. Over the past 12 months, SPARC stock gained 54.8074%.
SPARC is not paying dividends to its shareholders.
The last earnings report, released on May 18, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Sun Pharma Advanced Research Company Ltd. has completed 1 stock splits, with the recent split occurring on Aug 23, 2012.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XNSE (INR).
SPARC Chart
People also search for
Sun Pharma Advanced Research Company Ltd. (SPARC) FAQ
What is the stock price today?
The current price is ₹207.38.
On which exchange is it traded?
Sun Pharma Advanced Research Company Ltd. is listed on XNSE.
What is its stock symbol?
The ticker symbol is SPARC.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 42.66B.
Has Sun Pharma Advanced Research Company Ltd. ever had a stock split?
Sun Pharma Advanced Research Company Ltd. had 1 splits and the recent split was on Aug 23, 2012.
Sun Pharma Advanced Research Company Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Anilkumar Raghavan CEO | XNSE Exchange | Y8240G100 CUSIP |
| India Country | 316 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Sun Pharma Advanced Research Company Limited operates as a biopharmaceutical entity primarily engaged in the discovery, development, and marketing of pharmaceutical formulations on a global scale. The company's primary research efforts are directed towards addressing critical therapeutic areas such as oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. Incorporated in 2006 and headquartered in Mumbai, India, the company has established its presence both within the domestic market and internationally, committing to the advancement of novel pharmaceutical solutions.
Products and Services
The company's portfolio includes a range of products aimed at improving patient outcomes in its target therapeutic areas. Here are notable examples:
- Elepsia XR: This advanced formulation of levetiracetam serves as an anti-epileptic agent designed to manage epilepsy. Elepsia XR underscores the company's contribution towards enhancing the quality of life for individuals afflicted with this disorder.
- Xelpros: A latanoprost ophthalmic emulsion, Xelpros is indicated for patients with open-angle glaucoma or ocular hypertension, showcasing the company's focus on addressing critical needs in ophthalmology.
- Phenobarbital Injection: Targeted at the treatment of neonatal seizures, this product highlights the company's commitment to providing essential medications for acute pediatric conditions.
- SDN-037: Currently in phase 3 clinical trials, SDN-037 is a formulation of difluprednate developed for treating inflammation and pain associated with ocular surgery, representing the company's ongoing efforts in post-operative care innovations.
- PDP-716: This product, aimed at treating glaucoma, is in phase 3 clinical trial and exemplifies the company's dedication to combating major causes of blindness.
- Vodobatinib (SCO-088): Dedicated to the treatment of resistant chronic myelogenous leukemia, Vodobatinib has completed part A of the Phase 1 study, illustrating the company's strides in tackling complex oncology challenges.
- Vodobatinib (SCC-138): In phase 2 clinical trial for Parkinson's disease treatment, this represents the company's innovative approach towards neurodegenerative disorders.
- SCD-044: Currently in phase 2 clinical trial for psoriasis and atopic dermatitis, SCD-044 highlights the company's focus on dermatological conditions and immune response disorders.
- SCO-120: This product is in phase 1 clinical trial for hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, signifying the company's contributions towards targeted cancer therapy.
Contact Information
Address: 17/B, Mahal Industrial Estate
Phone: 91 22 6645 5645
Website: https://sparc.life
